arGenX SE is a global immunology company founded in 2008, dedicated to developing life-changing solutions for people living with severe autoimmune diseases. Its core work centers on antibody engineering and building an antibody innovation ecosystem, operating within the biopharmaceutical industry.
The company's lead product, VYVGART (efgartigimod alfa), is a first-in-class neonatal Fc receptor blocker. It is approved for the treatment of generalized myasthenia gravis and is being explored for potential application across dozens of other severe autoimmune conditions.
arGenX operates with a stated philosophy of co-creation, guided by cultural pillars of Innovation, Co-creation, Excellence, Humility, and Empowerment. The company describes its work as being driven by urgency and a commitment to advancing immunology for patients with significant unmet medical needs.
